Cart
sales@molnova.com
Monobehenin
CAS No. 30233-64-8
Monobehenin( —— )
Catalog No. M24226 CAS No. 30233-64-8
Monobehenin has a strong inhibitory effect on the formation of bacterial biofilm.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 50MG | 34 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameMonobehenin
-
NoteResearch use only, not for human use.
-
Brief DescriptionMonobehenin has a strong inhibitory effect on the formation of bacterial biofilm.
-
DescriptionMonobehenin has a strong inhibitory effect on the formation of bacterial biofilm.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number30233-64-8
-
Formula Weight432.68
-
Molecular FormulaC25H52O5
-
Purity>98% (HPLC)
-
SolubilityDMSO: 1 mg/mL (2.31mM);H2O: insoluble
-
SMILESCCCCCCCCCCCCCCCCCCCCCC(O)=O.OCC(O)CO
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Pivette P, et al. Polymorphism of glyceryl behenates: from the individual compounds to the pharmaceutical excipient. Chem Phys Lipids. 2014 Oct;183:191-203.
molnova catalog
related products
-
PACAP-38 (31-38), hu...
PACAP-38 (31-38), human, mouse, rat demonstrates potent, efficacious, and sustained stimulatory effects on sympathetic neuronal NPY and catecholamine production.
-
JHU-083
JHU-083, a proagent of 6-diazo-5-oxo-L-norleucine (DON), is an orally active and selective glutaminase antagonist. JHU-083 blocks glutaminase activity in brain CD11b+ cells and experimental cerebral malaria (ECM) resulting in a net decrease of glutamate levels in the animals.
-
Ac-[Tyr1,D-Phe2]-GRF...
[Ac-Tyr1,D-Phe2]GRF 1-29, amide (human), a growth hormone releasing factor (GRF) analogue, is a vasoactive intestinal peptide (VIP) antagonist.
